Japan Asia Investment
VC Fund
Tokyo, Japan
Japan Asia Investment is a VC fund in Tokyo focused on Medical and Internet. JAIC is Japan's largest independent venture capital firm and has accumulated experience and know-how over a period of 15 years as a pioneer of venture capital investments in Asia. Building on such strengths, they are establishing a globally linked organization that pursues investment opportunities centering on the three regions of Japan, Asia, and the United States.
- Total investments:
- 46
- Last investment:
- Lead investor:
- 15%
- Fund size:
- $50M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Japan Asia Investment invests in
Stages Japan Asia Investment invests in
Countries Japan Asia Investment invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 7 contacts → | |||
Round size
- Series B
- $2.3M–$40M
- Series C
- $5M–$33M
- Venture - Series Unknown
- $444k–$4.5M
Investment Focus
Industry
- Medical 7 (15%)
- Internet 6 (13%)
- Health Care 6 (13%)
- Biotechnology 6 (13%)
- Software 5 (11%)
Stage
- Venture - Series Unknown 12 (26%)
- Series B 10 (22%)
- Series C 5 (11%)
- Funding Round 5 (11%)
- Seed 3 (7%)
Country
- Japan 26 (57%)
- United States 8 (17%)
- China 1 (2%)
- Romania 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Hiroyuki Misawa
Managing Director
|
Managing Director | Total investments: 11 | Find email | |
|
Hidetaka Fukuzawa
Managing Directors
|
Managing Directors | Total investments: 0 | Find email | |
|
Keizai Doyukai
Founder
|
Founder | Total investments: 0 | Find email | |
|
Kenjiro Kanaya
Standing Corporate Auditor
|
Standing Corporate Auditor | Total investments: 0 | Find email | |
|
Makoto Isshi
Senior Managing Director
|
Senior Managing Director | Total investments: 0 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| KIC Holdings engages in asset management, securitization, investment, advisory services,and real estate development businesses. They offer detailed services for due diligence, acquisition, financing, management planning, and asset management for medium- to large-size distribution centres, warehouses, and trunk rooms. | Venture - Series Unknown / Mar 01, 2020 | ||
| Integral Geometry Science is a specialized manufacturer of measuring equipment and signal / image processing software. | $4.6M / Venture - Series Unknown / Sep 13, 2019 | ||
| Last One Mile provides the infrastructure to allow connections between telecommunications facility and its customers | $443.5K / Venture - Series Unknown / Nov 01, 2018 | ||
| Megakaryon Corporation is a medical Research Company. | $32.7M / Series C / Dec 25, 2017 | ||
| NIPPON SOUKEN is a Risk management support for analyzing all risks. | $441.7K / Venture - Series Unknown / Dec 07, 2017 | ||
| CROCO offers solutions for implementing content marketing, including current situation analysis, policy formulation, planning, production, editing, proofreading, submission, coding, effect measurement, maintenance, and operation. | Private Equity / Aug 01, 2017 | ||
| REGiMMUNE Corporation is a private biopharmaceutical company developing innovative solutions for treating immune disorders caused by nonspecific and/or excessive immune reactions. REGiMMUNE uses its proprietary technology platform, reVax (reverse vaccination), to target immune tolerance against specific disease-causing antigens throughinduction of regulatory T cells (Treg). This technology has potential applications in a number of immune system disorders and diseases including Graft versus Host Disease (GvHD), type 1 diabetes mellitus (T1DM), rheumatoid arthritis (RA), multiple sclerosis (MS) and systemic lupus erythematosus (SLE).Currently, the company has one clinical-stage compound in a Phase I/II trial in the United States (RGI-2001) as a treatment for GvHD associated with hematopoietic stem cell transplantation and has a second product in preclinical development (RGI-3001) as a new treatment for T1DM. In addition, it has a number of well-differentiated compounds in its research-stage pipeline.In healthy individuals, the normal immune system works to protect humans from disease-causing viruses, bacterium, and cancers; or foreign antigens such as peanuts, wheat and tree pollens. Conventional immunosuppressants have several significant side effects associated with long-term administration including risk of infection, toxicity and relapse. Products developed with ReVax technology are expected to reduce or eliminate such side effects as well as reduce long-term treatment. | $5.7M / Series E / May 10, 2017 | ||
| FacePeer is a development and operation of Facehub, a video call platform for companies, and Viewhub, a web interview service specializing in job interviews. The company provides optimal solutions according to the operating system and issues. By enhancing operational effectiveness and changing work practices, FacePeer not only supports thelong-term expansion of businesses but also fosters a connected society where everyone can grow. | $1.7M / Venture - Series Unknown / May 10, 2017 | ||
| Laxus Technologies is an E-Commerce start up. | $12.4M / Series B / Jan 25, 2017 | ||
| J-ARM is the animal cellular medicine business. | Venture - Series Unknown / Sep 02, 2016 | ||
| See all 46 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Japan Asia Investment invest in?
Japan Asia Investment invests primarily in Medical, Internet and Health Care startups, most often at Venture - Series Unknown and Series B stage. Most of the 46 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Japan Asia Investment invest in?
Japan Asia Investment typically joins rounds of $2.3M–$40M at Series B, $5M–$33M at Series C and $444k–$4.5M at Venture - Series Unknown. These are whole funding-round sizes, not Japan Asia Investment's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Japan Asia Investment took part in.
How do I contact Japan Asia Investment?
Public channels for Japan Asia Investment include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Japan Asia Investment?
The team at Japan Asia Investment includes Hiroyuki Misawa (Managing Director), Hidetaka Fukuzawa (Managing Directors) and Keizai Doyukai (Founder), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
